Nyxoah
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Belgium · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Rue Edouard Belin 12, Mont-Saint-Guibert...Phone Number
+3210222355Website
www.nyxoah.comRevenue
$25 MillionStock Symbol
NYXHIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Nyxoah
Nyxoah, located in Mont-Saint-Guibert, Belgium, is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.Explore more
Nyxoah Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nyxoah your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Nyxoah has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nyxoah launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Nyxoah recently announced quarterly report
Check out if Nyxoah is spiking on competitors!
Funding: Get notified immidiatlly once Nyxoah has new funding data
Click to see if Nyxoah had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Nyxoah, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Nyxoah
Recommended Actions
Reach out to Masked Content who joined Nyxoah as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Nyxoah is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nyxoah is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nyxoah.
Nyxoah financials insights
Gather financial insights about Nyxoah, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$11M
2016
Private Equity
$20M
2020
Private Equity
$27.2M
Stock Offering
$99.6M
2023
Share Placement
$15M
2024
Share Placement
$27M
2025
Stock/Share Issuance
$77M
2026
Private Equity
$95M
Nyxoah Tech Stack
A closer look at the technologies used by Nyxoah
Most Recent Scoops
Project
Nyxoah has achieved a stable AGNS market share of up to 25% overall in Germany, its largest AGNS market outside the United States.
Proof of Concept (POC), Business Development
Project
hosted an Investor Day on July 8, 2026, featuring leading ENT surgeons, sleep physicians, and independent reimbursement experts who shared firsthand Genio implant experience, confirmed strong airway openings on activation, and validated the durability of long-term coverage and Genio's positioning under future coding scenarios.
Medical Research, Finance, Investor Relations
Earnings
reported cash and cash equivalents plus financial assets totaling approximately EUR 97.8 million as of June 30, 2026.
Accounting, Financial Reporting, Finance
Earnings
reported an operating loss of EUR 20.6 million for Q2 2026, compared to EUR 19.9 million in Q2 2025, with Q2 2026 operating expenses including a one-time non-cash share-based compensation charge of approximately EUR 900,000 due to the repricing of employee equity incentive awards.
Earnings, Business Finance, Finance
Earnings
Earnings, Finance
Nyxoah News & Media
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?
Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 […]Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® SystemNyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
REGULATED INFORMATION INSIDE INFORMATION
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nyxoah
Sign Up For FreeTo access detailed company insights
Nyxoah, located in Mont-Saint-Guibert, Belgium, is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.... Read More
